Mina Abdolahi 1,2 , Payam Sarraf 3 , Mohammad Hassan Javanbakht 2 , Niyaz Mohammadzadeh Honarvar 2 , Mahsa Hatami 2 , Neda Soveyd 2 , Abbas Tafakhori 3 , Mohsen Sedighiyan 4 , Mona Djalali 5 , Arash Jafarieh 1 , Yousef Masoudian 1 , Mahmoud Djalali 2 Show Affiliations »
Abstract
Show RCT »
Hide RCT «
BACKGROUND: Migraine is a disabling neuroinflammatory condition characterized by increasing the levels of interleukin (IL)-6, a proinflammatory cytokine and C-reactive protein (CRP) which considered as a vascular inflammatory mediator, disrupting the integrity of blood-brain barrier and contributing to neurogenic inflammation, and disease progression. Curcumin and ω-3 fatty acids can exert neuroprotective effects through modulation of IL-6 gene expression and CRP levels. The aim of present study is the evaluation of combined effects of ω-3 fatty acids and nano-curcumin supplementation on IL-6 gene expression and serum level and hs-CRP levels in migraine patients . METHODS: Eighty episodic migraine patients enrolled in the trial and were divided into four groups as 1) combination of ω-3 fatty acids (2500 mg) plus nano-curcumin (80 mg), 2) ω-3 (2500 mg), 3) nanocurcumin (80 mg), and 4) the control (ω-3 and nano-curcumin placebo included oral paraffin oil ) over a two-month period. At the beginning and the end of the study, the expression of IL-6 from peripheral blood mononuclear cells and IL-6 and hs-CRP serum levels were measured, using a real-time PCR and ELISA methods, respectively. RESULTS: The results showed that both of ω-3 and nano-curcumin down-regulated IL-6 mRAN and significantly decreased the serum concentration . hs-CRP serum levels significantly decrease in combination and nano-curcumin within groups (P<0.05). An additive greater reduction of IL-6 and hs-CRP was observed in the combination group suggested a possible synergetic relation. CONCLUSION: It seems that ω-3 fatty acids and curcumin supplementation can be considered a new promising target in migraine prevention. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
RCT Entities: Population
Interventions
Outcomes
BACKGROUND: Migraine is a disabling neuroinflammatory condition characterized by increasing the levels of interleukin (IL)-6 , a proinflammatory cytokine and C-reactive protein (CRP ) which considered as a vascular inflammatory mediator, disrupting the integrity of blood-brain barrier and contributing to neurogenic inflammation , and disease progression. Curcumin and ω-3 fatty acids can exert neuroprotective effects through modulation of IL-6 gene expression and CRP levels. The aim of present study is the evaluation of combined effects of ω-3 fatty acids and nano-curcumin supplementation on IL-6 gene expression and serum level and hs-CRP levels in migraine patients . METHODS: Eighty episodic migraine patients enrolled in the trial and were divided into four groups as 1) combination of ω-3 fatty acids (2500 mg) plus nano-curcumin (80 mg), 2) ω-3 (2500 mg), 3) nanocurcumin (80 mg), and 4) the control (ω-3 and nano-curcumin placebo included oral paraffin oil ) over a two-month period. At the beginning and the end of the study, the expression of IL-6 from peripheral blood mononuclear cells and IL-6 and hs-CRP serum levels were measured, using a real-time PCR and ELISA methods, respectively. RESULTS: The results showed that both of ω-3 and nano-curcumin down-regulated IL-6 mRAN and significantly decreased the serum concentration. hs-CRP serum levels significantly decrease in combination and nano-curcumin within groups (P<0.05). An additive greater reduction of IL-6 and hs-CRP was observed in the combination group suggested a possible synergetic relation. CONCLUSION: It seems that ω-3 fatty acids and curcumin supplementation can be considered a new promising target in migraine prevention. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Chemical
Disease
Gene
Species
Keywords:
Curcumin; high sensitivity C-reactive protein; interleukin-6; migraine; ω-3 fatty acids.
Mesh： See more »
Substances： See more »
Year: 2018
PMID： 29938621 DOI： 10.2174/1871527317666180625101643
Source DB: PubMed Journal: CNS Neurol Disord Drug Targets ISSN： 1871-5273 Impact factor: 4.388